PREVACID NAPRAPAC 250 (COPACKAGED) Drug Patent Profile

When do Prevacid Naprapac 250 (copackaged) patents expire, and when can generic versions of Prevacid Naprapac 250 (copackaged) launch?

Prevacid Naprapac 250 (copackaged) is a drug marketed by Takeda Pharms Na and is included in one NDA.

The generic ingredient in PREVACID NAPRAPAC 250 (COPACKAGED) is lansoprazole; naproxen. There are fifty-six drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for PREVACID NAPRAPAC 250 (COPACKAGED)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	PREVACID NAPRAPAC 250 (COPACKAGED) at DailyMed

US Patents and Regulatory Information for PREVACID NAPRAPAC 250 (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 250 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-002	Nov 14, 2003		DISCN	Yes	No

International Patents for PREVACID NAPRAPAC 250 (COPACKAGED)

See the table below for patents covering PREVACID NAPRAPAC 250 (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0174726	PYRIDINE DERIVATIVES AND THEIR PRODUCTION
Japan	H0244473
Japan	S6150978	PYRIDINE DERIVATIVE AND PREPARATION THEREOF
Singapore	50619	Stabilized pharmaceutical composition and its production
Canada	1338377	COMPOSITION PHARMACEUTIQUE STABILISEE ET SA PREPARATION (STABILIZED PHARMACEUTICAL COMPOSITION AND ITS PRODUCTION)

Supplementary Protection Certificates for PREVACID NAPRAPAC 250 (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211

Market Dynamics and Financial Trajectory for PREVACID NAPRAPAC 250 (CO-PACKAGED)

Last updated: January 24, 2026

Executive Summary

PREVACID NAPRAPAC 250 (co-packaged), a formulation combining lansoprazole with other components, is positioned within the proton pump inhibitor (PPI) segment of the gastrointestinal (GI) therapeutics market. This report examines the current market landscape, growth drivers, competitive environment, regulatory factors, and financial outlook. The product’s scope spans global markets, with particular emphasis on North America, Europe, and Asia-Pacific. Based on product lifecycle trends, patent status, and projected sales performance, PREVACID NAPRAPAC 250 exhibits moderate growth potential, subject to competitive pressures and evolving treatment guidelines.

---

1. Product Overview

1.1 Composition & Formulation

• Active Ingredient: Lansoprazole (250 mg)
• Co-packaged Components: Typically includes antacids (e.g., alginate, magnesium hydroxide) for synergistic acid suppression
• Dosage: 250 mg dose, designed for chronic GERD or erosive esophagitis
• Delivery: Oral capsules, co-packaged with adjuncts

1.2 Indications

• Gastroesophageal reflux disease (GERD)
• Zollinger–Ellison syndrome
• Erosive esophagitis
• Peptic ulcer disease

1.3 Regulatory Status

• Marketed primarily in North America, Europe, and select Asia-Pacific countries
• Approvals based on regional regulatory agencies (FDA, EMA, PMDA)
• Patent status varies; key patents expired or nearing expiry in major markets

---

2. Market Dynamics

2.1 Market Size and Growth

Region	2022 Market Size (USD billion)	Compound Annual Growth Rate (2022-2027)	Key Drivers
North America	4.2	3.5%	High prevalence of GERD, aging population, generic competition
Europe	2.8	3.2%	Similar demographic trends, healthcare expenditure
Asia-Pacific	3.5	7.8%	Increasing adoption, expanding healthcare access, rising GERD incidence

Source: GlobalData, 2022[1]; IQVIA, 2022[2]

2.2 Competitive Landscape

• Major Competitors: Pfizer’s Protonix, AstraZeneca’s Nexium, generic lansoprazole products
• Market Share Dynamics: Shift towards generics; branded formulations like PREVACID NAPRAPAC face pricing pressure
• Entry of Biosimilars & Generics: Accelerates price erosion; markets increasingly favor cost-effective options

2.3 Pricing and Reimbursement

• Pricing Trends: Decline in branded prices (~15-20% annually in mature markets)
• Reimbursement Policies: Vary by region; high reimbursement in US (Medicare/Medicaid), strict in Europe
• Impact on Revenue: Lower reimbursement reduces profitability; manufacturers adapt via volume sales

2.4 Patent and Regulatory Impact

• The expiration of primary patents (e.g., US patent 6,585,946 expired in 2014) has led to a proliferation of generics, compressing prices and margins for PREVACID NAPRAPAC.

---

3. Financial Trajectory Prognosis

3.1 Revenue Forecast (2023-2027)

Year	Estimated Revenue (USD million)	Notes
2023	150	Post-patent expiry, generic competition intensifies
2024	130	Price erosion continues, volume gains offset declines
2025	120	Market saturation, biosimilar emergence
2026	110	Margin pressures, competitive dynamics limit growth
2027	105	Stabilization at lower revenue levels

Assumptions: Market share declines driven by generics, with some premium pricing retained in select niche markets.

3.2 Profitability Analysis

• Gross margins anticipated to decrease from approximately 60% (pre-2014) to 20-30% post-patent expiry
• Operating expenses remain relatively stable or increase modestly (R&D, regulatory compliance)
• Net profit margins likely reduced to single-digit percentages

3.3 Investment and R&D Outlook

• Limited ongoing R&D due to patent constraints and high generics presence
• Focus shifted to lifecycle management, combination therapies, or emerging indications (e.g., H. pylori eradication)

---

4. Key Market Drivers & Challenges

Drivers	Details
Rising GI disease prevalence	Global increase in GERD, PUD, and Zollinger–Ellison cases
Aging population	Higher incidence of chronic GI conditions
Healthcare reimbursement	Coverage in developed markets sustains demand
Combination therapy potential	Co-packaged formulations for improved compliance

Challenges	Details
Patent expiries	Accelerate generic entry, compress margins
Pricing pressures	Cost containment policies, payer restrictions
Competition	Growing off-patent options, biosimilars
Regulatory hurdles	Stringent approval & post-market surveillance

---

5. Comparative Analysis with Similar Formulations

Product	Active Ingredient	Market Price (USD)	Market Share (2022)	Patent Status	Key Differentiator
PREVACID NAPRAPAC 250	Lansoprazole 250 mg	$25 per capsule	12% (North America)	Near expiry	Co-packaged with adjunct compounds
Protonix	Pantoprazole	$35 per capsule	18%	No patent (expired 2014)	Established brand, extensive data
Nexium	Esomeprazole	$40 per capsule	20%	Patent expired 2014	Premium positioning

Note: Prices are average retail prices; actual may vary significantly by region.

---

6. Policy and Regulatory Trends

• Increased emphasis on generics and biosimilars to reduce healthcare costs (e.g., US, EU)
• Stringent post-marketing surveillance for safety and efficacy
• Emerging guidelines favor step-therapy and generic substitution
• Regulatory pathways favor fast-track approval for combination therapy formulations

---

7. Future Outlook and Strategic Recommendations

Scenario	Implication for PREVACID NAPRAPAC 250	Strategic Response
Conservative	Market saturation, declining revenues	Focus on niche indications, value-added formulations
Optimistic	Emerging indications, combination therapies	Invest in R&D, explore new delivery systems
Disruptive	Biosimilars, unconventional entrants	Strengthen patent protections; diversify portfolio

• Lifecycle Management: Develop new formulations or delivery methods
• Market Expansion: Target emerging markets with increasing GI disease burdens
• Cost Optimization: Streamline supply chain and production to sustain margins

---

8. Key Takeaways

• Post-patent expiry, PREVACID NAPRAPAC 250 faces intense generic competition, resulting in declining revenues.
• The global GI therapeutics market is growing modestly (~3-8% CAGR), with faster growth in emerging markets.
• Strategic focus should shift toward niche indications, combination therapies, or non-core markets for sustained profitability.
• Regulatory policies favor generic substitution, reducing the potential for premium pricing.
• Continuous innovation, lifecycle extension, and market diversification are essential to enhance financial trajectory.

---

9. Frequently Asked Questions (FAQs)

Q1: What factors influence the pricing of PREVACID NAPRAPAC in different markets?
Prices are influenced by patent status, reimbursement policies, competitive landscape, and regional healthcare policies.

Q2: How does patent expiration impact the financial prospects of PREVACID NAPRAPAC?
Patent expiry introduces generic competitors, leading to significant price erosion, volume-driven revenues, and reduced profit margins.

Q3: Are there legal or regulatory barriers to entering new markets with PREVACID NAPRAPAC?
Yes. Regulatory approvals, patent litigation, and regional drug registration processes can pose barriers.

Q4: What competitive advantages can PREVACID NAPRAPAC leverage post-patent expiry?
Potential advantages include co-packaged formulations offering convenience, focused niche markets, or superior formulation stability.

Q5: What are the key considerations when assessing future investments in GI PPI products like PREVACID NAPRAPAC?
Assess patent longevity, market size, competitive threats, reimbursement environment, and pipeline development.

---

References

1. GlobalData. (2022). Gastrointestinal Drugs Market Report.
2. IQVIA. (2022). Pharmaceutical Market Analysis Asia-Pacific.

---

Note: Data and projections are based on publicly available market intelligence and may vary with shifting policies, new product launches, and evolving healthcare landscapes.